IARC 60th Anniversary - 19-21 May 2026
Session : 19/05/26 - Posters
Development and Validation of an Epidemiological Risk Score for Early Detection of PC in High-Risk Individuals within the IMAGene Project
RIOBÓ-MAYO L. 2, OLIVERI S. 3, BOURNET B. 4, TOMASZ K. W. 5, BALACESCU O. 6, OBÓN-SANTACANA M. 1,2, MORENO V. 1,2
1 Institut Catalŕ d'Oncologia, Hospitalet de Llobregat, Spain; 2 Institut d’Investigació Biomčdica de Bellvitge , Hospitalet de Llobregat, Spain; 3 IEO European Institute of Oncology IRCCS, Milan, Italy; 4 Rangueil Hospital and University of Toulouse, Toulouse, France; 5 Pomeranian Medical University in Szczecin, Szczecin, Poland; 6 The Oncology Institute “Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania
Background: Early detection is critical in pancreatic ductal adenocarcinoma (PDAC), one of the most lethal malignancies due to its typically late diagnosis.
Objectives: In this study, we aimed to validate an Epidemiological Risk Score (ERS) designed to identify individuals at increased risk of developing PDAC prior to the use of imaging or other diagnostic procedures.
Methods: The ERS was constructed through a meta-analysis of 24 well-established epidemiological risk factors. We applied this score to a prospective cohort of 178 high-risk individuals with a family history of PDAC within the IMAGene project (ClinicalTrials.gov registration code: NCT06334458). To evaluate its predictive value, all participants underwent whole-body or abdominal MRI, and imaging findings were classified according to ONCO-RADS criteria to identify and categorize lesions based on their malignant potential. External validation was conducted using a subset of the UK Biobank cohort (≈ 300, 000 individuals), among whom 1,648 were diagnosed with PDAC.
Results: Higher ERS values were associated with the presence of potentially malignant lesions on MRI. Both pancreatic and extra-pancreatic malignant lesions were more frequent among individuals with higher ERS scores (P < 0.05) compared to controls. External validation in PDAC cases within the UK Biobank cohort confirmed these associations.
Conclusions: Our findings support the integration of the ERS as a feasible, low-cost tool for PDAC risk stratification, with the potential to facilitate earlier detection and improve clinical outcomes